Texas Pharmacy Loses License Over Risky Drug Fills
Published Date: 4/14/2025
Notice
Summary
Mariste Pharmacy in Texas lost its DEA license because it kept filling risky prescriptions without checking for abuse and broke important drug storage and record rules. They didn’t ask for a hearing to defend themselves, so the suspension and revocation stand. This means Mariste can’t legally handle controlled drugs anymore, protecting public safety starting from May 2024.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA revokes Mariste Pharmacy registration
The Drug Enforcement Administration revoked Mariste Pharmacy's DEA Certificate of Registration No. FM2279431. The final Order revoking the registration is effective May 14, 2025, which means Mariste Pharmacy no longer holds a DEA registration to distribute or dispense controlled substances.
Immediate suspension issued May 20, 2024
On May 20, 2024, the DEA issued an Order to Show Cause and Immediate Suspension of Registration for Mariste Pharmacy under 21 U.S.C. 824(d), finding the continued registration could be an imminent danger to public health or safety. That suspension preceded the final revocation.
DEA denies pending and future Texas registrations
The Order also denies any pending applications of Mariste Pharmacy to renew or modify this registration and denies any other pending application for additional registration in Texas. This denial is part of the final action effective May 14, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-06311 — Eagle Pharmacy; Decision and Order
Eagle Pharmacy in Houston lost its DEA license because it filled risky prescriptions without fixing warning signs, breaking federal and Texas laws. They missed the deadline to ask for a hearing, so the decision to revoke their registration stands. This means Eagle Pharmacy can no longer legally handle controlled substances, affecting their business and customers immediately.
Next: 2025-06318 — National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a closed virtual meeting on May 8, 2025, to review important grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies, ensuring their ideas stay private and protected. No public attendance or money changes are involved, but this review helps decide which projects get support.